The global head and neck squamous cell carcinoma market is set for steady growth, driven by advancements in treatment options, increasing awareness of early cancer detection, and rising demand for ...
Approval based on results of landmark Phase 3 C-POST trial that show Libtayo is first immunotherapy to significantly improve disease-free ...
Regeneron Pharmaceuticals has won expanded European approval of its blockbuster cancer drug Libtayo for certain patients with skin cancer. Regeneron on Wednesday said the European Commission's nod ...
This segment offers an up-to-date overview of current treatment standards and diagnostic practices in advanced esophageal ...
The FDA has granted approval to sevabertinib (Hyrnuo) for the treatment of patients with locally advanced or metastatic, ...
TARRYTOWN, N.Y., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human ...
Extreme heat and plenty of sunshine is a given for Atlanta, especially this summer. In June, there were nearly 285 hours of sunshine, and we’re on track for more rays this month, according to U.S.
An expert explains how gene-expression profile testing can inform treatment decisions for patients with squamous cell carcinoma. Gene-expression profile (GEP) testing among patients with squamous cell ...
The U.S. Food and Drug Administration on Wednesday said it has approved Bayer's drug for patients with a type of lung cancer ...
The U.S. Food and Drug Administration said on Wednesday that it has approved Bayer's drug for patients with a form of lung ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback